236 related articles for article (PubMed ID: 21394210)
1. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.
Clegg NJ; Couto SS; Wongvipat J; Hieronymus H; Carver BS; Taylor BS; Ellwood-Yen K; Gerald WL; Sander C; Sawyers CL
PLoS One; 2011 Mar; 6(3):e17449. PubMed ID: 21394210
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
[TBL] [Abstract][Full Text] [Related]
3. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
4. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Nandana S; Ellwood-Yen K; Sawyers C; Wills M; Weidow B; Case T; Vasioukhin V; Matusik R
Prostate; 2010 May; 70(6):591-600. PubMed ID: 19938013
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.
Kladney RD; Cardiff RD; Kwiatkowski DJ; Chiang GG; Weber JD; Arbeit JM; Lu ZH
Cancer Res; 2010 Nov; 70(21):8937-47. PubMed ID: 20940396
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
Majumder PK; Febbo PG; Bikoff R; Berger R; Xue Q; McMahon LM; Manola J; Brugarolas J; McDonnell TJ; Golub TR; Loda M; Lane HA; Sellers WR
Nat Med; 2004 Jun; 10(6):594-601. PubMed ID: 15156201
[TBL] [Abstract][Full Text] [Related]
7. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
8. Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions.
Benavides F; Blando J; Perez CJ; Garg R; Conti CJ; DiGiovanni J; Kazanietz MG
Cell Cycle; 2011 Jan; 10(2):268-77. PubMed ID: 21224724
[TBL] [Abstract][Full Text] [Related]
9. Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.
Ko YH; Miyake H; Behnsawy HM; Cheon J; Fujisawa M
Urol Int; 2014; 93(2):146-51. PubMed ID: 24556942
[TBL] [Abstract][Full Text] [Related]
10. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.
Majumder PK; Yeh JJ; George DJ; Febbo PG; Kum J; Xue Q; Bikoff R; Ma H; Kantoff PW; Golub TR; Loda M; Sellers WR
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7841-6. PubMed ID: 12799464
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
12. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
13. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
Lee SH; Poulogiannis G; Pyne S; Jia S; Zou L; Signoretti S; Loda M; Cantley LC; Roberts TM
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11002-7. PubMed ID: 20534477
[TBL] [Abstract][Full Text] [Related]
14. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
15. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
16. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
17. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
18. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
20. The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.
Floc'h N; Abate-Shen C
Oncotarget; 2012 Dec; 3(12):1483-4. PubMed ID: 23242005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
